Logan, M. , Mackinder, M., Clark, C. M., Kountouri, A., Jere, M., Ijaz, U. Z. , Hansen, R., McGrogan, P., Russell, R. K. and Gerasimidis, K. (2022) Intestinal fatty acid binding protein is a disease biomarker in paediatric coeliac disease and Crohn’s disease. BMC Gastroenterology, 22, 260. (doi: 10.1186/s12876-022-02334-6) (PMID:35606704) (PMCID:PMC9125891)
![[img]](https://eprints.gla.ac.uk/style/images/fileicons/text.png) |
Text
270913.pdf - Published Version Available under License Creative Commons Attribution. 1MB |
Abstract
Background: There is a clinical need to develop biomarkers of small bowel damage in coeliac disease and Crohn’s disease. This study evaluated intestinal fatty acid binding protein (iFABP), a potential biomarker of small bowel damage, in children with coeliac disease and Crohn’s disease. Methods: The concentration iFABP was measured in plasma and urine of children with ulcerative colitis, coeliac disease, and Crohn’s disease at diagnosis and from the latter two groups after treatment with gluten free diet (GFD) or exclusive enteral nutrition (EEN), respectively. Healthy children (Controls) were also recruited. Results: 138 children were recruited. Plasma but not urinary iFABP was higher in patients with newly diagnosed coeliac disease than Controls (median [Q1, Q3] coeliac disease: 2104 pg/mL 1493, 2457] vs Controls: 938 pg/mL [616, 1140], p = 0.001). Plasma or urinary iFABP did not differ between patients with coeliac on GFD and Controls. Baseline iFABP in plasma decreased by 6 months on GFD (6mo GFD: 1238 pg/mL [952, 1618], p = 0.045). By 12 months this effect was lost, at which point 25% of patients with coeliac disease had detectable gluten in faeces, whilst tissue transglutaminase IgA antibodies (TGA) continued to decrease. At diagnosis, patients with Crohn’s disease had higher plasma iFABP levels than Controls (EEN Start: 1339 pg/mL [895, 1969] vs Controls: 938 pg/mL [616, 1140], p = 0.008). iFABP did not differ according to Crohn’s disease phenotype. Induction treatment with EEN tended to decrease (p = 0.072) iFABP in plasma which was no longer different to Controls (EEN End: 1114 pg/mL [689, 1400] vs Controls: 938 pg/mL [616, 1140], p = 0.164). Plasma or urinary iFABP did not differ in patients with ulcerative colitis from Controls (plasma iFABP, ulcerative colitis: 1309 pg/mL [1005, 1458] vs Controls: 938 pg/mL [616, 1140], p = 0.301; urinary iFABP ulcerative colitis: 38 pg/mg [29, 81] vs Controls: 53 pg/mg [27, 109], p = 0.605). Conclusions: Plasma, but not urinary iFABP is a candidate biomarker with better fidelity in monitoring compliance during GFD than TGA. The role of plasma iFABP in Crohn’s disease is promising but warrants further investigation.
| Item Type: | Articles |
|---|---|
| Additional Information: | ML PhD studentship was funded by the Engineering and Physical Sciences Research Council and Nestle Health Science though they had no impact on study design, analysis or conclusions reached. UZI is supported by NERC Independent Research Fellowship NE/L011956/1. |
| Status: | Published |
| Refereed: | Yes |
| Glasgow Author(s) Enlighten ID: | Russell, Dr Richard and Logan, Dr Michael and Mackinder-Jonas, Mary and Gerasimidis, Professor Konstantinos and Ijaz, Dr Umer and Hansen, Dr Richard and Clark, Clare |
| Authors: | Logan, M., Mackinder, M., Clark, C. M., Kountouri, A., Jere, M., Ijaz, U. Z., Hansen, R., McGrogan, P., Russell, R. K., and Gerasimidis, K. |
| College/School: | College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing College of Science and Engineering > School of Engineering > Infrastructure and Environment |
| Journal Name: | BMC Gastroenterology |
| Publisher: | BioMed Central |
| ISSN: | 1471-230X |
| ISSN (Online): | 1471-230X |
| Copyright Holders: | Copyright © 2022 The Authors |
| First Published: | First published in BMC Gastroenterology 22:260 |
| Publisher Policy: | Reproduced under a Creative Commons License |
University Staff: Request a correction | Enlighten Editors: Update this record
Funder and Project Information
Funder and Project Information